Hypertriglyceridemia induced by S-1: A novel case report and review of the literature.

Abstract

INTRODUCTION:

S-1, a compounding agent of tegafur, gimeracil, and oteracil potassium, is one of the most effective chemotherapeutic agents for colorectal cancer. In this case, following S-1 administration, we observed predominant elevation of serum triglyceride.

CASE REPORT:

A 49-year-old man with stage IV transverse colon adenocarcinoma received S-1 + irinotecan + bevacizumab. At the end of the S-1 administration period in every course, his serum triglyceride level was found to be elevated. Finally, it reached grade 4, without any symptoms of acute pancreatitis in the fifth course, and fenofibrate 80 mg once a day was administered.Management & outcome: Interestingly, the elevation spontaneously normalized without any pharmacotherapy 14 days after S-1 withdrawal, and this elevation did not occur when S-1 was not administered. Further, fenofibrate administration attenuated the hypertriglyceridemia to grades 1-3, with no complications.

DISCUSSION:

S-1 administration induced hypertriglyceridemia owing to the elevated serum triglyceride; however, a contrasting result was observed in the S-1 withdrawal period and during the S-1-cessation cycle. Since dietary intake was poorer during the S-1 administration period, it is considered that S-1 might have disturbed lipid metabolism. Further, we know that capecitabine, which is a prodrug of fluorouracil, also induces hypertriglyceridemia. As the end product of these medicines is fluorouracil, the presence of fluorouracil or its metabolizing enzymes, the genetic background of the patient might have affected the results. We have to be aware of the risk of asymptomatic and temporal occurrence of hypertriglyceridemia by S-1 administration for the early detection with appropriate pre-emptive treatment.

• Authors: Yoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara
• Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (J Oncol Pharm Pract) Vol. 27 Issue 4 Pg. 1020-1025 (Jun 2021) ISSN: 1477-092X [Electronic] England
• PMID: 32936722 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Antimetabolites, Antineoplastic
• Drug Combinations
• S 1 (combination)
• Tegafur
• Oxonic Acid

Topics

• Acute Disease
• Antimetabolites, Antineoplastic (adverse effects)
• Colonic Neoplasms (blood, drug therapy)
• Drug Combinations
• Humans
• Hypertriglyceridemia (blood, chemically induced, diagnosis)
• Male
• Middle Aged
• Oxonic Acid (adverse effects)
• Tegafur (adverse effects)